Results for tag: "Luxturna"

Luxturna is a gene therapy drug used to treat inherited retinal diseases caused by mutations in the RPE65 gene. It is the first and only FDA-approved gene therapy for an inherited retinal disease. Luxturna is administered as a single intravitreal injection into the eye and works by delivering a healthy copy of the RPE65 gene to the retina, allowing it to produce the protein needed for normal vision. The drug is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, a rare genetic disorder that can lead to blindness. The Luxturna market is a rapidly growing segment of the optical disorders drugs market. It is driven by the increasing prevalence of inherited retinal diseases, the growing awareness of gene therapy, and the increasing availability of Luxturna. The market is expected to continue to grow in the coming years as more patients are diagnosed and treated with the drug. Some of the key players in the Luxturna market include Spark Therapeutics, Novartis, Genentech, and Roche. Show Less Read more